Is PFE or PHAT more undervalued in 2026?

CirclFi compares Pfizer, Inc. (PFE) and Phathom Pharmaceuticals, Inc. (PHAT) using 13 institutional-grade valuation models. PFE has a Quality of Company score of 6.7/10 while PHAT scores 6.1/10.

Which is a better buy — PFE or PHAT?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PFE and PHAT valuations compare?

PFE at $26.18 and PHAT at $9.59 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PFE vs PHAT Valuation Comparison 2026 — Intrinsic Value Analysis

PFE

Pharmaceutical Preparations

Pfizer, Inc.

Quality

6.7

out of 10

Value Trap

SAFE

Price

$26.18

Last close

Models

12/13

Active

PHAT

Pharmaceutical Preparations

Phathom Pharmaceuticals, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$9.59

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	PFE Fair Value	PFE Upside	PHAT Fair Value	PHAT Upside
Bayesian DCF	Intrinsic	$29.37	+12.2%	$3.58	-62.7%
Earnings Power Value	Intrinsic	$32.38	+23.7%	$5.33	-55.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PFE vs PHAT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PFE vs PHAT — Which Stock Is More Undervalued?

PFE scores higher with a 6.7/10 quality rating vs PHAT's 6.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pfizer, Inc. (PFE) and Phathom Pharmaceuticals, Inc. (PHAT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PFE currently trades at $26.18 with a QOC of 6.7/10, while PHAT trades at $9.59 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).